Antizol

This page contains recent news articles, when available, and an overview of Antizol but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results - ‎Nov 5, 2009‎
...$29992 $17022 $77789 $45757 ======= ======= ======= ======= (1) The Company sold its rights to and interests in Antizol and Antizol-Vet in August 2008. ... Reuters

Jazz Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and ... - ‎Nov 13, 2009‎
The company's products list include Xyrem, for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy, Antizol and Luvox CR ... PR-inside.com (press release)

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.